Overview

Phase I Clinical Study of BR105 Injection

Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
A phase 1, dose escalation and dose expansion study of BR105 in patients with advanced malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd